Fabry Disease Gene Therapy Using Liver-Targeted AAV Enzyme Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Fabry disease, such as enzyme replacement therapy, are costly, require lifelong administration, and many patients develop neutralizing antibodies, while gene therapy offers a potential cure but faces challenges in achieving effective and sustained enzyme expression.
Innovation Solution
A codon-optimized α-galactosidase A gene is delivered using an adeno-associated viral vector (AAV) specifically targeted to the liver, leveraging liver-specific promoters for high expression and metabolic cross-correction mechanisms to reduce antibody formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is used, then treatment effectiveness is improved, but cost and requirement for lifelong administration increase
Solution Approach 1:
The patent applies self-service by enabling the patient's own liver to produce the therapeutic enzyme through gene therapy. The AAV vector delivers the functional α-galactosidase A gene to hepatocytes, which then autonomously produce and secrete the enzyme to correct the disease, eliminating the need for lifelong external enzyme administration.
Solution Approach 2:
The patent uses copying by introducing a functional copy of the α-galactosidase A gene into the patient's liver cells. This genetic copy enables the liver to produce the therapeutic enzyme continuously, replacing the need for ongoing external enzyme therapy.
2Reliability
If enzyme replacement therapy is used, then treatment effectiveness is improved, but development of neutralizing antibodies increases
Solution Approach 1:
The patent reduces antibody development by having the patient's own liver produce the enzyme through gene therapy, rather than receiving external enzyme preparations. This endogenous production minimizes the immunogenic response and neutralizing antibody formation that occurs with conventional ERT.
Solution Approach 2:
The patent uses an intermediary approach by employing AAV vectors as carriers to deliver the therapeutic gene. The viral vector serves as a transient intermediary that facilitates gene transfer without requiring continuous exposure to the therapeutic protein, thereby reducing antibody development.
3Reliability
If conventional gene therapy approach is used, then potential for cure is achieved, but expression level and duration are insufficient
Solution Approach 1:
The patent applies parameter changes by optimizing the AAV vector constructs with specific promoter elements and transcriptional control mechanisms. These modifications enhance the transcriptional activity and protein expression levels of the therapeutic gene, ensuring sufficient enzyme production for therapeutic effect.
Solution Approach 2:
The patent uses local quality by employing liver-specific promoters and targeting the therapy to hepatocytes. This ensures high expression of the therapeutic enzyme specifically in the liver, where it can be effectively secreted to correct the disease, rather than attempting uniform expression throughout the body.
4Object-generated harmful factors
If low levels of enzyme correction are used, then risk of neutralizing antibodies is reduced, but correction of distant cells is insufficient
Solution Approach 1:
The patent enables distant cell correction through self-service by having the liver produce and secrete α-galactosidase A that circulates systemically. The enzyme is released into the bloodstream and can be taken up by distant cells through metabolic cross-correction, allowing widespread therapeutic effect without requiring direct gene delivery to each tissue.
Solution Approach 2:
The patent uses the circulating enzyme as an intermediary mechanism to correct distant cells. The liver-produced enzyme acts as a mobile intermediary that can reach and correct substrate accumulation in various organs through blood circulation, enabling systemic treatment with a single liver-targeted therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in sustained and effective production of functional α-galactosidase A, potentially reducing storage of glycosphingolipids and ameliorating disease symptoms without the need for continuous administration, while minimizing antibody development.
Implementation Method 1
gene therapy for Fabry disease offers the potential for a cure through persistent, endogenous production of α-galactosidase A following the transfer of a normal copy of the α-galactosidase A gene to an affected patient
Implementation Method 2
the novel codon optimised sequence of SEQ ID NO. 1 results in increased expression of the α-galactosidase A protein in hepatocytes transduced with an AAV vector under the control of a liver specific promoter
Implementation Method 3
correction of a small number of cells will potentially correct distant cells too as a result of metabolic cross-correction mechanisms, wherein corrected cells secrete α-galactosidase A that can correct bystander cells
Implementation Method 4
Fabry disease is a rare X-linked inherited multisystem lysosomal storage disorder, with an estimated prevalence of approximately 1:40,000. It is caused by a deficiency of the α-galactosidase A enzyme resulting in the accumulation of neutral glycosphingolipids in the lysosomes
Data Source
AI summary
There is described a nucleic acid molecule comprising a nucleotide sequence encoding for a functional α-galactosidase A protein wherein the nucleotide sequence has at least 85% identity to the sequence of SEQ ID NO. 1. Also described is a vector, host cell or transgenic animal comprising the nucleic acid molecule; and a pharmaceutical composition comprising the nucleic acid molecule or the vector. Further, the use of the nucleic acid molecule in a method of treating Fabry disease is described.